Clinical trials: Dental Occlusion
Blood Pressure
Tourniquets Increase Proximal Pressure
There is an urgent clinical need to improve survival and neurologic outcomes after cardiac arrest. When a patient goes into cardiac arrest, cardiopulmonary resuscitation (CPR) with chest compressions is the current standard of…
- Trial name
- NCT05324306
- Testing
- combat application tourniquets (CAT)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Angina, Chronic Coronary Occlusion
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
The objectives of this post-marketing surveillance, conducted in Japan, is to know the frequency, type and degree of device malfunction, to assure the safety of the medical device, and to collect information on evaluation of the…
- Conditions
- Angina, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- NCT01086228
- Testing
- XIENCE V / PROMUS stent
- Where
- 47 sites in Japan
- Volunteers
- 2,010 people
- Sponsor
- Abbott Medical Devices
Carotid Artery Stenosis
GORE Embolic Protection With Reverse Flow
To compare the 30-day safety and efficacy of the GORE Flow Reversal System when used with approved carotid stents to an Objective Performance Criterion derived from distal embolic protection studies.
- Trial name
- EMPiRE (NCT00594100)
- Testing
- GORE Flow Reversal System (GFRS)
- Where
- 2 sites in United States
- Volunteers
- 245 people
- Sponsor
- W.L.Gore & Associates
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to…
- Trial name
- CRUISE (NCT00485836)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 392 people
- Sponsor
- Genentech, Inc.
Dental Caries
Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions
Objectives: Occlusal surfaces of erupting permanent molars are highly prone to caries. Self-assembling peptide (P11-4) has proven to enhance biomimetic mineralization of early carious lesions.
- Trial name
- NCT02724592
- Testing
- self assembling peptide P11-4 (Curodont™ Repair), fluoride varnish (Duraphat®)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Non-Ischemic Central Retinal Vein Occlusion
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
- Trial name
- NCT01295112
- Testing
- Active bevacizumab and Active dexamethasone
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Texas Retina Associates
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia
CDH is a birth defect characterized by the development, very early in gestation, of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen.
- Trial name
- CHOP_FETO (NCT02549820)
- Testing
- GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital of Philadelphia
Retinal Vein Occlusion, Macular Edema
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular function and recalcitrant macular edema associated with retinal vein occlusion following treatment with 2 or more prior intravitreal…
- Trial name
- NCT01449682
- Testing
- Ozurdex
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Retina Macula Institute
Stroke
Visualization of Cerebral Arteries Using Contrast-Enhanced Transcranial Ultrasound in Stroke Patients
The purpose of this study is to find out more about the usefulness of ultrasound in combination with a contrast solution to look for blood vessel blockage or occlusion in the brains of stroke patients.
- Trial name
- NCT00282841
- Testing
- ultrasound
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of California, San Diego
Hidradenitis Suppurativa, Hidradenitis
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body.
- Conditions
- Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils
- Trial name
- NCT03275870
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Elena Gonzalez Brant, MD
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Coronary Artery Disease
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®).
- Trial name
- NCT00307047
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 3,687 people
- Sponsor
- Abbott Medical Devices
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \& CRUISE trials and subsequently followed in the HORIZON extension trial.
- Trial name
- RETAIN (NCT01198327)
- Testing
- ranibizumab, Peripheral Laser
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Peter A Campochiaro, MD
Chronic Total Occlusion, Ischemic Heart Disease
Chronic Total Occlusion Percutaneous Coronary Intervention Study
The objective of this study is to evaluate angiographic confirmation of placement of any guidewire beyond the CTO, in the true vessel lumen, in patients undergoing CTO percutaneous coronary intervention (PCI) in which at least…
- Conditions
- Chronic Total Occlusion, Ischemic Heart Disease, Chronic Total Occlusion of Coronary Artery
- Trial name
- CTO-PCI (NCT03988166)
- Testing
- Chronic Total Occlusion Revascularization, GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vascular Solutions LLC
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including…
- Conditions
- Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
- Trial name
- RAVEN (NCT01471691)
- Testing
- ranibizumab 0.5mg, ranibizumab 1.0mg
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Hanscom, Thomas, M.D.
Occlusion
Comparison of EVD Catheter Diameter on Occlusion and Replacement
A randomized trial comparing small versus large catheters in terms of occlusion and need for replacement to confirm differential occlusion risk based on catheter size.
- Trial name
- NCT03248739
- Testing
- Clear Bactiseal 'large' catheter (EVD), Orange Bactiseal 'small' catheter (EVD)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Wake Forest University Health Sciences
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
Stroke, Acute
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours.
- Trial name
- TEMPO-2 (NCT02398656)
- Testing
- Tenecteplase, Antiplatelet treatment
- Where
- 61 sites in Australia, Austria and 8 more
- Volunteers
- 1,274 people
- Sponsor
- University of Calgary
Macular Edema
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)
This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).
- Trial name
- NCT01445626
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Allergan